Lupin Ltd(NSI:LUPIN.NS - News), India's No. 4 drug maker by revenue, may come from the land of cheap generics but it is betting on high-margin branded drugs in the United States to drive growth.

Z entiva Group has entered into a licence and supply agreement with pharmaceutical company Lupin for the commercialisation of ...

New Delhi: Drug major Lupin is looking to strengthen its branded and specialty business in the US by launching new products, brand acquisitions and even buyout of other specialty companies which ...

Lupin is joining the list of genericsmakers looking toward branded drugs for growth. The Indian company is scouting for U.S. brands to buy, President Nilesh Gupta tells Bloomberg, particularly in ...

Domestic pharma majors Lupin, Sun Pharma and Cipla have dominated the list of top reputed pharmaceuticals brand survey released today. City-based Lupin Pharmaceuticals tops in reputation leading ...

Lupin has been exclusively marketing these brands in the Indian market since July 2021 under a distribution and promotion agreement with A. Menarini India Private Limited. This strategic acquisition ...

Lupin acquires five legacy brands from Menarini for Rs 101 crore. Brands are in gastroenterology, urology and anti-infectives. Acquisition strengthens Lupin's diverse portfolio and Menarini's ...

Lupin Ltd<LUPN.NS>, India's No. 4 drug maker by revenue, may come from the land of cheap generics but it is betting on high-margin branded drugs in the United States to drive growth.

Lupin Ltd, India's No. 4 drug maker by revenue, may come from the land of cheap generics but it is betting on high-margin branded drugs in the United States to drive growth.